Increased peripheral blood CD5+ B cells predict earlier conversion to MS in high-risk clinically isolated syndromes

Multiple Sclerosis Journal

Volumn 17, Issue 6, 2011, Pages 690-694

  Villar, Luisa M ^a,b   Espiño, Mercedes ^a,b   Roldán, Ernesto ^a,b   Marín, Nieves ^a,b   Costa Frossard, Lucienne ^a,b   Muriel, Alfonso ^a,b   Álvarez Cermeño, José C ^a,b,c  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b INSTITUTO RAMÓN Y CAJAL DE INVESTIGACIÓN SANITARIA IRYCIS   (Spain)

^c UNIVERSITY OF ALCALÁ   (Spain)

Author keywords

CIS; multiple sclerosis

Indexed keywords

CD5 ANTIGEN; IMMUNOGLOBULIN G; OLIGOCLONAL BAND;

ADULT; ARTICLE; B LYMPHOCYTE; CLINICAL ASSESSMENT; CLINICALLY ISOLATED SYNDROME; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; FOLLOW UP; HIGH RISK PATIENT; HUMAN; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NEUROIMAGING; PREDICTION; PREDICTIVE VALUE; RELAPSE; STEROID THERAPY; SYNDROME;

EID: 79959459343     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458510396922     Document Type: Article

References (19)

1. Berger T. Current therapeutic recommendations in multiple sclerosis. J Neurol Sci. 2009 ; 287 (Suppl. 1). S37 - S45
2. Korteweg T, Tintoré M, Uitdehaag B, Rovira A, Frederiksen J, Miller D, et al. MRI criteria for dissemination in space in patients with clinically isolated syndromes: a multicentre follow-up study. Lancet Neurol. 2006 ; 5: 221-227 (Pubitemid 43238345)
3. Masjuan J, Álvarez-Cermeño JC, García-Barragán N, Díaz-Sánchez M, Espiño M, Sádaba MC, et al. Clinically isolated syndromes: a new oligoclonal band test accurately predicts conversion to MS. Neurology. 2006 ; 66: 576-578 (Pubitemid 43739891)
4. Tintoré M, Rovira A, Río J, Tur C, Pelayo R, Nos C, et al. Do oligoclonal bands add information to MRI in first attacks of multiple sclerosis?. Neurology. 2008 ; 70: 1079-1083 (Pubitemid 351464763)
5. Youinou P, Mackenzie LE, Lamour A, Mageed RA, Lydyard PM. Human CD5-positive B cells in lymphoid malignancy and connective tissue diseases. Eur J Clin Invest. 1993 ; 23: 139-150 (Pubitemid 23089124)
6. Seidi OA, Semra YK, Sharief MK. Expression of CD5 on B lymphocytes correlates with disease activity in patients with multiple sclerosis. J Neuroimmunol. 2002 ; 133: 205-210 (Pubitemid 35346743)
7. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol. 1983 ; 13: 227-231 (Pubitemid 13158528)
8. Luque R, García-Trujillo JA, Cámara C, Moreno A, Eiras P, Roy G, et al. CD106 and activated-CD29 are expressed on myelomatous bone marrow plasma cells and their downregulation is associated with tumour progression. Br J Haematol. 2002 ; 119: 70-78 (Pubitemid 35176500)
9. Pencina MJ, D'Agostino RB, D'Agostino RB, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med. 2008 ; 27: 157-172 (Pubitemid 351193639)
10. Berger T, Rubner P, Schautzer F, Egg R, Ulmer H, Mayringer I, et al. Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N Engl J Med. 2003 ; 349: 139-145 (Pubitemid 36818783)
11. Kuhle J, Pohl C, Mehling M, Edan G, Freedman MS, Hartung HP, et al. Lack of association between antimyelin antibodies and progression to multiple sclerosis. N Engl J Med. 2007 ; 356: 371-378 (Pubitemid 46148779)
12. Sellebjerg F, Jensen J, Jensen CV, Wiik A. Expansion of CD5 B cells in multiple sclerosis correlates with CD80 (B7-1) expression. Scand J Immunol. 2002 ; 56: 101-107 (Pubitemid 35304381)
13. Corcione A, Casazza S, Ferretti E, Giunti D, Zappia E, Pistorio A, et al. Recapitulation of B cell differentiation in the central nervous system of patients with multiple sclerosis. Proc Natl Acad Sci U S A. 2004 ; 101: 11064-11069 (Pubitemid 38989584)
14. Cepok S, Rosche B, Grummel V, Vogel F, Zhou D, Sayn J, et al. Short-lived plasma blasts are the main B cell effector subset during the course of multiple sclerosis. Brain. 2005 ; 128: 1667-1676 (Pubitemid 41373685)
15. Magliozzi R, Howell O, Vora A, Serafini B, Nicholas R, Puopolo M, et al. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain. 2007 ; 130: 1089-1104 (Pubitemid 47355604)
16. Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008 ; 358: 676-688 (Pubitemid 351240747)
17. Böhm I. Increased PB B-cells expressing the CD5 molecules in association to autoantibodies in patients with lupus erythematosus and evidence to selectively down-modulate them. Biomed Pharmacother. 2004 ; 58: 338-343 (Pubitemid 38759733)
18. Matsushita T, Yanaba K, Bouaziz JD, Fujimoto M, Tedder TF. Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression. J Clin Invest. 2008 ; 118: 3420-3430
19. Niino M, Hirotani M, Miyazaki Y, Sasaki H. Memory and naïve B-cell subsets in patients with multiple sclerosis. Neurosci Lett. 2009 ; 464: 74-78